Check out the companies making headlines before the bell. GoDaddy — Shares dropped 9% after the company forecasted annual revenue below estimates, citing slow AI-related adoption. GoDaddy said it expects its revenue to come in between $5.195 billion and $5.275 billion this year, falling short of analysts' consensus estimate of $5.28 billion, according to FactSet. Lowe's — The home improvement reta...
Check out the companies making headlines before the bell. GoDaddy — Shares dropped 9% after the company forecasted annual revenue below estimates, citing slow AI-related adoption. GoDaddy said it expects its revenue to come in between $5.195 billion and $5.275 billion this year, falling short of analysts' consensus estimate of $5.28 billion, according to FactSet. Lowe's — The home improvement retailer's shares tumbled about 3% after it issued lower-than-expected forward guidance for its bottom line through January 2027. The company forecasted earnings in the range of $12.25 - $12.75 per share excluding some items for the period, falling below analysts' consensus estimate of $12.90, per FactSet. However, Lowe's beat on its adjusted earnings and revenue for the fourth quarter of last year. "While the housing macro remains pressured, we are focused on directing what is within our control, which includes our ongoing productivity initiatives," Lowe's said Wednesday in a statement. First Solar — Shares of the solar technology company slid 17% on the back of weak fourth-quarter earnings results and full-year guidance. First Solar earned $4.84 per share for the quarter, while analysts polled by LSEG expected $5.15 per share. Revenue came out at $1.68 billion, beating analysts' consensus expectation of $1.56 billion, however. For the full year, First Solar guided revenue to come out between $4.9 billion and $5.2 billion, significantly lower than the $6.12 billion expected. Cava Group — Shares of the Mediterranean restaurant chain jumped 11% after its fourth-quarter results and its fiscal 2026 outlook topped estimates. Cava earned 4 cents a share on revenue of $275 million, while analysts surveyed by LSEG anticipated earnings of 3 cents per share on revenue of $268 million. The company also reported full-year revenue of more than $1 billion for the first time. Looking ahead, Cava expects sales at restaurants open at least a year will rise between 3% and 5% in 2026. Workday — ...
Zura Bio Limited ( ZURA ) priced an underwritten public offering of 18.2M Class A ordinary shares at $6.25/share. The company is also offering 1.8M pre-funded warrants at $6.249 each, reflecting the $6.25 share price. All shares and pre-funded warrants in the offering are being sold directly by Zura Bio. Zura granted underwriters a 30-day option to purchase up to an additional 3M Class A ordinary ...
Zura Bio Limited ( ZURA ) priced an underwritten public offering of 18.2M Class A ordinary shares at $6.25/share. The company is also offering 1.8M pre-funded warrants at $6.249 each, reflecting the $6.25 share price. All shares and pre-funded warrants in the offering are being sold directly by Zura Bio. Zura granted underwriters a 30-day option to purchase up to an additional 3M Class A ordinary shares at the public offering price. The offering is expected to generate ~$125M in gross proceeds. The transaction is anticipated to close on February 26, 2026. ZURA shares down 5.4% premarket. More on Zura Bio Zura Bio announces proposed public offering of class A ordinary shares, pre-funded warrants Zura Bio appoints Sandeep Kulkarni as CEO Seeking Alpha’s Quant Rating on Zura Bio Historical earnings data for Zura Bio Financial information for Zura Bio
Morsa Images/DigitalVision via Getty Images Update Coverage on Cronos I last talked about Cronos ( CRON ) in March 2025 and I opined that the stock is a “Strong Buy.” Since that discussion, Cronos stock has trended higher by 38%. As I write an update thesis, I maintain my bullish view on Cronos. I believe that fundamental developments have been positive and point to meaningful value creation in th...
Morsa Images/DigitalVision via Getty Images Update Coverage on Cronos I last talked about Cronos ( CRON ) in March 2025 and I opined that the stock is a “Strong Buy.” Since that discussion, Cronos stock has trended higher by 38%. As I write an update thesis, I maintain my bullish view on Cronos. I believe that fundamental developments have been positive and point to meaningful value creation in the next 24 to 36 months. This renewed thesis discusses the factors that are likely to be growth catalysts. The focus is on the company’s fundamentals, expansion plans, and a possible industry-level catalyst that can trigger significant price-action. It’s also worth noting that Cronos is due to report Q4 2025 earnings soon. With capacity expansion coupled with inroads in international markets likely to yield positive results, it’s a good time to consider exposure pre-results. One factor that I have emphasized in the past is Cronos being attractively valued. As of Q3 2025, Cronos reported a cash buffer of $784 million. A market capitalization of $1 billion underscores the view on depressed valuation. Without doubt, cash in the balance sheet will be of little importance if it’s not directed towards scaling-up operations. Cronos is however deploying cash for organic and acquisition driven growth. This factor will be elaborated in the thesis. It’s also worth mentioning at the onset that Altria ( MO ) continues to hold 40.89% stake in Cronos. With a strong backing, I don’t see financing of aggressive growth as a concern once regulatory headwinds wane for the cannabis sector. Catalyst of International Expansion An important point to note is that the cannabis industry was plagued with over capacity, cash burn, and regulatory headwinds. Given these circumstances, Cronos has made a slow, but steady, progress in the right direction. The focus has been on conserving cash, streamlining operations, and gradually building presence in global markets. Prior to 2023, Cronos has operated in Ca...
(RTTNews) - Hut 8 Corp. (HUT, HUT.TO) reported a fourth quarter net loss from continuing operations of $301.8 million compared to profit of $149.7 million, prior year. Adjusted EBITDA was negative at $347.9 million compared to profit of $310.6 million. Total revenue increased to
(RTTNews) - Hut 8 Corp. (HUT, HUT.TO) reported a fourth quarter net loss from continuing operations of $301.8 million compared to profit of $149.7 million, prior year. Adjusted EBITDA was negative at $347.9 million compared to profit of $310.6 million. Total revenue increased to
coffeekai/iStock via Getty Images Astera Labs ( ALAB ) shares slipped fractionally in premarket trading on Wednesday as Citi put the semiconductor company on a negative catalyst watch. “While we continue to think ALAB is well placed in the AI ecosystem and is adding more optical capabilities longer term, we estimate that over the short term the company will continue to be viewed as the main copper...
coffeekai/iStock via Getty Images Astera Labs ( ALAB ) shares slipped fractionally in premarket trading on Wednesday as Citi put the semiconductor company on a negative catalyst watch. “While we continue to think ALAB is well placed in the AI ecosystem and is adding more optical capabilities longer term, we estimate that over the short term the company will continue to be viewed as the main copper-focused AI networking company,” analyst Atif Malik wrote in a note to clients. “Therefore, we think that over the next 30 days, ALAB stock sentiment will likely be pressured heading to and coming out of OFC as key optical announcements highlighting potential displacement of copper-based solutions will be in focus.” Malik has a Buy rating and a $250 price target on Astera Labs. More on Astera Labs Astera Labs: Most Attractive AI Crash Of The Season Astera Labs: The Market's Overreaction Hands Long-Term Buyers A Gift The AI Memory Supercycle: Why Astera Labs And Marvell Are Top Buys SA Asks: Which hardware stocks are best positioned for AI? SA Asks: Which software stocks are best positioned for AI?
coffeekai/iStock via Getty Images Astera Labs ( ALAB ) shares rose fractionally in premarket trading on Wednesday even as Citi put the semiconductor company on a 30-day negative catalyst watch. “While we continue to think ALAB is well placed in the AI ecosystem and is adding more optical capabilities longer term, we estimate that over the short term the company will continue to be viewed as the ma...
coffeekai/iStock via Getty Images Astera Labs ( ALAB ) shares rose fractionally in premarket trading on Wednesday even as Citi put the semiconductor company on a 30-day negative catalyst watch. “While we continue to think ALAB is well placed in the AI ecosystem and is adding more optical capabilities longer term, we estimate that over the short term the company will continue to be viewed as the main copper-focused AI networking company,” analyst Atif Malik wrote in a note to clients. “Therefore, we think that over the next 30 days, ALAB stock sentiment will likely be pressured heading to and coming out of OFC as key optical announcements highlighting potential displacement of copper-based solutions will be in focus.” Malik has a Buy rating and a $250 price target on Astera Labs. (This story has been updated to reflect share price movement.) More on Astera Labs Astera Labs: Most Attractive AI Crash Of The Season Astera Labs: The Market's Overreaction Hands Long-Term Buyers A Gift The AI Memory Supercycle: Why Astera Labs And Marvell Are Top Buys SA Asks: Which hardware stocks are best positioned for AI? SA Asks: Which software stocks are best positioned for AI?
Medline Inc. press release ( MDLN ): Q4 GAAP EPS of -$0.01 misses by $0.14 . Revenue of $7.8B (+14.8% Y/Y) beats by $290M . This was primarily driven by increased volumes, with strong growth from both the Medline Brand and Supply Chain Solutions segments. For full year 2026, the Company expects Organic Sales growth of 8% to 9% and Adjusted EBITDA of $3.5 to $3.6 billion. More on Medline Inc. Medli...
Medline Inc. press release ( MDLN ): Q4 GAAP EPS of -$0.01 misses by $0.14 . Revenue of $7.8B (+14.8% Y/Y) beats by $290M . This was primarily driven by increased volumes, with strong growth from both the Medline Brand and Supply Chain Solutions segments. For full year 2026, the Company expects Organic Sales growth of 8% to 9% and Adjusted EBITDA of $3.5 to $3.6 billion. More on Medline Inc. Medline Industries: Solid Physical Moat With Visible Earnings Growth Runway Medline Inc. (MDLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Medline Inc. (MDLN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Medline surges 28% as stock begins trading after $6.26B IPO draws heavy demand Medical supplier Medline prices IPO at $29, raises $6.26 billion
MGP Ingredients press release ( MGPI ): Q4 Non-GAAP EPS of $0.63 beats by $0.13 . Revenue of $138.3M (-23.5% Y/Y) beats by $5.46M . Adjusted EBITDA decreased 51% to $26.1 million. Capital expenditures of $31.9 million declined 56% from the year-ago level, and were largely in line with the company's expectations. Cash flow from operations increased $19.3 million to record-high level of $121.5 milli...
MGP Ingredients press release ( MGPI ): Q4 Non-GAAP EPS of $0.63 beats by $0.13 . Revenue of $138.3M (-23.5% Y/Y) beats by $5.46M . Adjusted EBITDA decreased 51% to $26.1 million. Capital expenditures of $31.9 million declined 56% from the year-ago level, and were largely in line with the company's expectations. Cash flow from operations increased $19.3 million to record-high level of $121.5 million. Net debt leverage ratio stands at approximately 2.0x as of December 31, 2025. 2026 Financial Guidance The consolidated financial guidance for 2026 includes: Sales are projected to be in the range of $480 million to $500 million consensus is $510.87M. Adjusted EBITDA is expected to be in the range of $90 million to $98 million. Adjusted basic EPS is expected to be in the $1.50 to $1.80 range (consensus is $2.44) , with weighted average basic shares outstanding of approximately 21.4 million, and an effective tax rate of approximately 27%. Full year capital expenditures are expected to be approximately $20 million. More on MGP Ingredients MGP Ingredients Is Not Broken, It's Just Hungover Seeking Alpha’s Quant Rating on MGP Ingredients Historical earnings data for MGP Ingredients Dividend scorecard for MGP Ingredients Financial information for MGP Ingredients
Charles River Laboratories ( CRL ) has signed a definitive agreement to divest certain European assets within its Discovery Services business to IQVIA Holdings ( IQV ) for ~$145M in cash. In addition to the initial proceeds, the transaction includes potential additional payments to Charles River of up to $10M. Charles River will retain other drug discovery capabilities totaling ~40% of its Discove...
Charles River Laboratories ( CRL ) has signed a definitive agreement to divest certain European assets within its Discovery Services business to IQVIA Holdings ( IQV ) for ~$145M in cash. In addition to the initial proceeds, the transaction includes potential additional payments to Charles River of up to $10M. Charles River will retain other drug discovery capabilities totaling ~40% of its Discovery Services revenue in 2025. The transaction is expected to close during the second quarter of 2026, subject to customary closing conditions. Separately, Charles River has signed a definitive agreement to divest its CDMO and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments. It will sell its CDMO sites in Tennessee, Maryland, and the United Kingdom and its Cell Solutions site in California. The businesses generated combined annual revenue of $143M in 2025. This transaction is expected to close during the second quarter of 2026, subject to customary closing conditions. The company is updating its financial guidance for 2026 to reflect the impact of the planned divestitures. The planned divestitures are expected to reduce reported revenue by slightly more than $200M in 2026, including more than a 50-basis-point reduction to organic revenue growth guidance. As a result, 2026 revenue, including divestiture impact, is expected to fall 3.5%-5%, compared to at least flat to +1.5% growth expected previously. The transactions are expected to generate at least 100 basis points of incremental non-GAAP operating margin improvement in 2026 and add around $0.10 to non-GAAP earnings per share for the partial year. Adjusted EPS is now expected in the range of $10.80 - $11.30 vs. $10.70 - $11.20 previously expected. More on IQVIA, Charles River Laboratories Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript Charles River Laboratories Q4 Review: Approaching A Bottom Charles River Laboratories International...
designer491/iStock via Getty Images Co-authored with Dislocation Capital If traditional bonds are like sedans and common stocks are like sports cars, convertible bonds are more like all-terrain vehicles. Showing versatility, as they can cruise steadily for income when markets are calm, but when conditions shift in their favor, they can adapt to capture upside. A convertible bond is a loan to a com...
designer491/iStock via Getty Images Co-authored with Dislocation Capital If traditional bonds are like sedans and common stocks are like sports cars, convertible bonds are more like all-terrain vehicles. Showing versatility, as they can cruise steadily for income when markets are calm, but when conditions shift in their favor, they can adapt to capture upside. A convertible bond is a loan to a company that pays interest like a regular bond but also gives the issuer an option to convert it into stock if the share price rises. Technology and growth companies tend to prefer them since they allow them to raise capital without dilution and pay a lower interest to issuers who accept lower coupons in exchange for upside potential. Convertible bonds had a breakout year in 2025, with global issuance reaching a record $166.5B, with U.S. companies accounting for nearly three-quarters of the total ( Source ), and our expectation is that this trend will continue into 2026 with large refinancing needs coming up ahead ( Morgan Stanley estimates $1.25T in corporate bond activity tied to maturities, calls, & tenders). A key reason convertibles remain attractive to us is the ability of a single issuance to change character to adapt across market regimes, shifting between being more sensitive to equity moves, credit moves, or behaving like a hybrid that catches the best of both worlds in various environments. This creates opportunities for skilled active managers to reposition portfolios in ways that wouldn’t be possible for purely equity or credit portfolios—making this space more suitable for actively managed CEFs. This adaptability is evidenced by how these assets perform in rising-yield environments: when the 10-year Treasury yield has historically increased by more than 100 basis points, convertible returns have tended to track equities more closely than bonds, avoiding some of the duration-driven drawdowns typical of rate-sensitive credit instruments. Source Calamos Over full ma...
APi Group press release ( APG ): Q4 Non-GAAP EPS of $0.44 beats by $0.03 . Revenue of $2.12B (+14.0% Y/Y) beats by $30M . Reported net revenues increased by 13.8% (11.1% organic) driven by growth in inspection, service, and monitoring revenues, strong growth in project revenues, acquisitions, and pricing improvements. For the full year 2026, the company expects: Net Revenues of $8,400 to $8,600 mi...
APi Group press release ( APG ): Q4 Non-GAAP EPS of $0.44 beats by $0.03 . Revenue of $2.12B (+14.0% Y/Y) beats by $30M . Reported net revenues increased by 13.8% (11.1% organic) driven by growth in inspection, service, and monitoring revenues, strong growth in project revenues, acquisitions, and pricing improvements. For the full year 2026, the company expects: Net Revenues of $8,400 to $8,600 million vs $8.46B consensus Adjusted EBITDA of $1,140 to $1,200 million Adjusted Free Cash Flow Conversion of approximately 115%, based on adjusted net income For the first quarter of 2026, the company expects: Net Revenues of $1,875 to $1,975 million vs $1.89B consensus Adjusted EBITDA of $225 to $235 million More on APi Group APi Group Corporation (APG) Presents at Barclays 43rd Annual Industrial Select Conference Transcript APi Group Corporation (APG) Presents at Citi's Global Industrial Tech & Mobility Conference 2026 Transcript APi Group: An Interesting Safe Player APi Group Q4 2025 Earnings Preview Key deals this week: Pinterest, Enova International, APi Group, Intel and more